NAR can not only reduce the lung injury induced by COVID-19 by inhibiting interleukin-6 (IL-6) [12], but also block LPS-induced pulmonary edema by inhibiting the secretion of MPO, tumor necrosis factor-α (TNF-α) and neutrophil infiltration [13]. This evidence concerns the gene IL6 and COVID-19.